Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...

“ [Trump’s plans] will come at the expense of potentially larger budget deficits, potentially larger debt and there is also ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

The Kroger Co. is recalling Home Chef Asian Style Chicken Stir Fry because meal kits contain cooked chicken which was recalled because of contamination with Listeria monocytogenes. According to ...

Canadians will get child benefit cheques this week amid Canada Post strike Canadians will get child benefit cheques this week amid Canada Post strike Parents who are expecting child benefit ...

The animated music star has drawn big crowds across the globe.